Anabella Nakhle from the University of Ottawa interviews Dr. Stephanie Willerth. Dr. Stephanie Willerth is the CEO of Axolotl Biosciences, a 3D bioprinting company in Victoria, BC. She is also a a Canada research chair and full professor of Biomedical Engineering at the University of Victoria, and an Adjunct Professor at the University of Missouri. In this episode, Dr. Willerth shares about her research in developing a 3D bioprinted Alzheimers disease model that replicated the native tissue environment.
Learn more: https://www.engr.uvic.ca/~willerth/
Anabella Nakhle (Voice), Serena Solari, Elie Njeime, and Mathania Vuningoma (Post-production, graphic designer and producer)
0:06| BeaTs and host introduction.
0:29 | Topic introduction.
0:59| Introduction to Dr. Willerth
1:47| Introduction to 3D bioprinting and bioink that was used for the disease model
2:43|Why was alzheimer's used as the disease model in this paper?
3:55 |Differences in modeling parkinson's disease vs alzheimer's disease.
4:30| Cell viability in the bioink
5:20| markers for cell death
6:00 | The future and challenges of 3D bioprinting in disease model development
7:14| Ethical issues that are faced with using patient-derived tissue
8:55| Ensuring the genotype of the induced pluripotent stem cells (iPSCs)
10:20| membrane potential of the bioprinted cells
11:10| Future involvement in the bioprinting field for listeners
Soundtrack by Funky Giraffe. All rights reserved. Listen more: